MiniMed Group Inc

MMED

Market cap $4.34B

MiniMed Group NASDAQ: MMED reported record fiscal 2026 revenue and outlined a slate of product launches it said will support faster growth in fiscal 2027, as management held the company's first earnings call as a standalone public company following its March IPO.

Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ: MMED), a global leader in diabetes technology, today announced an expanded agreement with Abbott to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems.

Continued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-year Record annual net sales performance surpasses $3B for first time, growing 14% as reported and 8% organic Advanced global pipeline ahead of schedule with FDA clearance for MiniMed Flex™, CE Mark for Instinct, and global launch of MiniMed Go™ Smart MDI NORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today reported financial results for its fourth quarter and full fiscal year ended April 24, 2026.

Following this week's launch of MiniMed Go™, MiniMed will bring hands-on demonstrations of the system and new clinical data NORTHRIDGE, Calif., May 27, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced an overview of its upcoming presence at the American Diabetes Association's (ADA) Scientific Sessions in New Orleans June 5-8.

NORTHRIDGE, Calif., May 26, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that management will participate in a fireside chat at the upcoming Goldman Sachs 47th Annual Global Healthcare Conference.

MiniMed study results show MiniMed 780G delivering consistent glycemic outcomes across sensors, reinforcing SmartGuard's strength.

Randomized crossover trial reinforces SmartGuard™ algorithm as key driver of automated insulin delivery performance NORTHRIDGE, Calif., May 21, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced results from a new randomized crossover study demonstrating that glycemic outcomes for study participants were virtually identical when using the MiniMed™ 780G system with either the Simplera Sync™ sensor or Instinct sensor, made by Abbott.

Diabetes equipment provider MiniMed is aiming to be the “self-driving car” of insulin pumps, says its CEO, Que Dallara. Hot off the heels of the company's IPO, Dallara speaks with Caroline Hyde on the sidelines of the Consello Spark Summit.

BRAMPTON, Ontario, April 28, 2026 (GLOBE NEWSWIRE) -- MiniMed Group, Inc. (MiniMed; Nasdaq: MMED), a global leader in insulin delivery, announced Health Canada has licensed new software for the MiniMed™ 780G system, marking a meaningful step forward in diabetes care for Canadians. With this authorization, the MiniMed™ 780G system now offers greater flexibility, combining Meal Detection™ technology, and SmartGuard™, with both the Guardian™ 4 and Simplera Sync™ sensors.

Investment bank Goldman Sachs just came out with calls on two under-the-radar stocks investors should get to know, and the sooner, the better.